A cut-off level of 5 ng/mL is used to define CEA elevation; cancer-specific mortality rates are higher and prognosis is poorer in patients with CRC showing preoperative serum CEA levels ≥5 ng/mL (44). This evidence concerns the gene CEACAM5 and colorectal carcinoma.